Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCDE: Adjuvant Bevacizumab, Metronomic CM, Diet and Exercise in Breast Cancer
NCT00925652Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2010
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Sep 2010; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00925652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00925652.